Netherlands’ Medicines Evaluations Board has ordered marketing authorization holders of promethazine-containing drugs to add to product packaging a warning about hallucinations as a possible side effect of use.
The regulator said it was acting after the national pharmacovigilance center, Bijwerkingencentrum Lareb, received 11 reports of hallucinations associated with...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?